Skip to Main Content

Rise and shine, everyone, another busy day is on the way. And after the presidential debate last night, being busy may be a good thing. Another good thing, of course, is a delicious cup of stimulation, which we are quaffing as we compose our prose. Please feel free to join us. Remember, no prescription is required. Meanwhile, here are some items of interest to get you going. We hope you have an especially productive day and, yes, do keep in touch …

Chicago plans to introduce an ordinance next month that would require pharmaceutical sales reps to carry a special license in hopes of fighting opioid addiction, the Chicago Tribune reports. Reps will have to track and provide, if requested, the number of health care providers they contacted, information about drugs promoted, samples provided, and whether doctors were compensated for their time. Names of doctors may also have to be supplied.

The Centers for Disease Control and Prevention has adopted a recommendation that preteens get two shots of an HPV vaccine instead of three and space them further apart, the Associated Press writes. Health officials want youngsters to get vaccinated at age 11 or 12, before most first have sex and could be infected, but less than one-third of 13-year-old boys and girls have gotten three doses.


Pfizer plans to appeal to the UK’s highest court a ruling last week that its patent for pregabalin, which is the active ingredient in Lyrica, for treating pain was invalid, Chemist and Druggist reports. A patent covering treatment of anxiety disorders and epilepsy expired, but another covering its use for pain relief does not expire until July 2017, and Pfizer has argued prescriptions for pain relief would violate that patent. The drug maker irked doctors with warnings.

A federal judge cleared Merck of allegations that it violated whistleblower protection laws by firing an analyst who raised concerns about a market research study, the Legal Intelligencer reports. The former analyst, Joni Westawski, claimed the drug maker improperly overpaid a third party firm for diabetes research and that she was illegally fired after questioning the arrangement.


The Food and Drug Administration granted accelerated approval to an Eli Lilly drug being developed to treat advanced soft tissue sarcomas, the Indianapolis Business Journal reports.

Crispr Therapeutics didn’t hit its target in its initial public offering, more evidence that investors are cooling on the CRISPR-Cas9 gene-editing technology, the Boston Globe says.

Sun Pharmaceutical signed a deal with the International Center for Genetic Engineering and Biotechnology to develop a novel dengue vaccine, the Economic Times writes.

An FDA advisory panel recommended the agency approve a low-dose nasal spray from Allergan for treating night-time urination, PharmaTimes tells us.

More than half of big drug makers now use Instagram for corporate accounts, according to PMLive.

Novartis signed an agreement with Cerulean Pharma, worth a potential $1.2 billion depending on milestones met, to co-develop nanoparticle drug conjugates, Pharmafile tells us.

The FDA will restructure and create a new Office of Tissues and Advanced Therapies, which was formerly known as the Office of Cellular, Tissue, and Gene Therapies, Regulatory Focus says.